,
2 min read
China’s pharmaceutical regulatory landscape has undergone significant reform with the introduction of the patent linkage system, a critical mechanism shaping drug registration in China and market entry strategies for both innovators and generic manufacturers.
Implemented under the amended Patent Law and associated measures, the system links patent status with marketing authorization approvals, creating a more structured and predictable pathway for resolving patent disputes.
What is China’s Patent Linkage System?
In China, the patent linkage system also known as the Drug Patent Dispute Early Resolution Mechanism connects the review of generic drug applications with the patent status of originator products.
The system ensures that potential patent disputes are addressed before marketing approval is granted, balancing innovation protection with timely access to generics.
A central feature is the Patent Information Registration Platform, managed by the National Medical Products Administration, which functions similarly to the U.S. Orange Book.
Key Features of the China Patent Linkage System
- 1. Patent Listing Platform
Marketing Authorization Holders (MAHs) must list relevant patents (e.g., active ingredient, formulation, and use patents) on the official platform.
As of early 2025, thousands of patents have already been registered, reflecting increasing industry adoption.
- 2. Generic Drug Patent Certifications
Generic applicants must submit patent declarations during generic drug registration in China, including:
- No relevant patent listed
- Patent expired/invalid or licensed
- Commitment to delay market entry until patent expiry
- Patent challenge (invalidity or non-infringement claim)
These declarations are central to the China drug approval process and determine the next regulatory steps.
- 3. Early Dispute Resolution Mechanism
If a generic applicant challenges a patent, the innovator company can initiate:
- Civil litigation
- Administrative adjudication
This must typically occur within a defined window after application disclosure, triggering a regulatory stay period.
- 4. Stay Period and Approval Hold
When a dispute is initiated, the National Medical Products Administration may impose a stay period (typically up to 9 months) during which approval of the generic drug is paused.
- 5. Market Exclusivity for First Generics
The first successful generic challenger may receive market exclusivity (typically 12 months), encouraging patent challenges and faster access to affordable medicines.
Recent Regulatory Developments Strengthening the System
China continues to enhance its pharmaceutical IP framework alongside patent linkage:
- Introduction of Patent Term Extension (PTE) for innovative drugs, extending protection to compensate for regulatory delays
- Ongoing refinements to data protection and exclusivity rules complementing patent linkage
- Increasing use of administrative adjudication and judicial routes for dispute resolution
Together, these mechanisms create a more comprehensive ecosystem for pharmaceutical patent protection in China.
Impact on Generic and Innovative Drug Companies
For Innovator Companies
- Stronger protection of intellectual property
- Earlier resolution of patent disputes
- Improved predictability of market exclusivity
For Generic Companies
- Clearer pathway for generic drug approval in China
- Opportunities for early market entry through patent challenges
- Increased competition for first-to-file advantages
Overall, the system is designed to balance innovation incentives with access to affordable medicines, aligning China with global regulatory practices.
Strategic Considerations for Market Entry
Companies entering the Chinese market should focus on:
- Accurate and timely patent listing strategies
- Strong regulatory and IP alignment during drug development
- Effective planning for generic drug certification pathways
- Monitoring evolving NMPA and IP regulations
A well-integrated regulatory and IP strategy is essential for success in the Chinese pharmaceutical market access.
Conclusion
China’s patent linkage system represents a major step forward in modernizing its pharmaceutical regulatory framework. By linking patent protection with drug approval, the system creates a more transparent and predictable environment for both innovators and generic manufacturers.
Ready to Navigate China’s Patent Linkage System?
Looking to streamline your drug registration in China and align with evolving patent linkage requirements? Freyr offers end-to-end support across regulatory strategy, patent linkage assessment, dossier preparation, and lifecycle management.
Connect with our experts today to accelerate your approvals and ensure compliance with National Medical Products Administration requirements.
